Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum

被引：15

作者：

Matsumura-Kimoto, Yayoi ^{[1
]}

Kuroda, Junya ^{[1
]}

Kaneko, Hitomi ^{[2
]}

Kamitsuji, Yuri ^{[3
]}

Fuchida, Shin-ichi ^{[4
]}

Nakaya, Aya ^{[5
]}

Shibayama, Hirohiko ^{[6
]}

Uoshima, Nobuhiko ^{[7
]}

Yokota, Isao ^{[8
]}

Uchiyama, Hitoji ^{[9
]}

Yagi, Hideo ^{[10
]}

Kosugi, Satoru ^{[11
]}

Matsui, Toshimitsu ^{[12
]}

Ishikawa, Jun ^{[13
]}

Matsuda, Mitsuhiro ^{[14
]}

Ohta, Kensuke ^{[15
]}

Iida, Masato ^{[16
]}

Tanaka, Hirokazu ^{[17
]}

Kobayashi, Masayuki ^{[18
]}

Wada, Katsuya ^{[3
]}

Shimazaki, Chihiro ^{[4
]}

Nomura, Shosaku ^{[5
]}

Imada, Kazunori ^{[2
]}

Hino, Masayuki ^{[19
]}

Matsumura, Itaru ^{[17
]}

Kanakura, Yuzuru ^{[6
]}

Takaori-Kondo, Akifumi ^{[18
]}

机构：

[1] Kyoto Prefectural Univ Med, Dept Med, Div Hematol & Oncol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan

[2] Japanese Red Cross Osaka Hosp, Dept Hematol, Osaka, Japan

[3] Matsushita Mem Hosp, Dept Hematol, Osaka, Japan

[4] Japan Community Hlth Care Org, Kyoto Kuramaguchi Med Ctr, Dept Hematol, Kyoto, Japan

[5] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan

[6] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Osaka, Japan

[7] Japanese Red Cross Kyoto Daini Hosp, Dept Hematol, Kyoto, Japan

[8] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biostat, Kyoto, Japan

[9] Japanese Red Cross Kyoto Daiichi Hosp, Dept Hematol, Kyoto, Japan

[10] Kinki Univ, Sch Med, Nara Hosp, Div Hematol, Nara, Japan

[11] Toyonaka City Hosp, Dept Hematol, Osaka, Japan

[12] Nishiwaki Municipal Hosp, Dept Hematol, Nishiwaki, Hyogo, Japan

[13] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Hematol & Oncol, Osaka, Japan

[14] PL Gen Hosp, Dept Hematol, Osaka, Japan

[15] Osaka Saiseikai Nakatsu Hosp, Dept Hematol, Osaka, Japan

[16] Kawasaki Hosp, Dept Hematol & Oncol, Kobe, Hyogo, Japan

[17] Kinki Univ, Dept Internal Med, Fac Med, Div Hematol & Rheumatol, Osaka, Japan

[18] Kyoto Univ, Dept Hematol & Oncol, Kyoto, Japan

[19] Osaka City Univ, Grad Sch Med, Dept Hematol, Osaka, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2018年 / 107卷 / 05期

基金：

日本学术振兴会;

关键词：

Multiple myeloma; Pomalidomide; Efficacy; Adverse events; LOW-DOSE DEXAMETHASONE; INTERNATIONAL STAGING SYSTEM; OPEN-LABEL; LENALIDOMIDE; SURVIVAL; TRIAL; EFFICACY; AGENTS; METAANALYSIS; DEGRADATION;

D O I：

10.1007/s12185-018-2416-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan. The subjects were 108 patients registered with the Kansai Myeloma Forum, who were treated with either POM or POM/DEX. Of these, 79 (73%), 73 (68%), and 58 (54%) were resistant to bortezomib (BTZ), lenalidomide (LEN), and both BTZ and LEN, respectively. The median overall survival (OS) was not reached. The median time to treatment failure (TTF) was 4.4 months. The best response was recorded in 96 patients, with a 31% overall response rate (ORR) and a 79% rate of achieving at least stable disease. Number of pre-POM regimens >= 5, non-IgG-type M-protein, and time from initial therapy to POM or POM/DEX therapy < 2 years were associated with shorter TTF and OS. Frequent (> 10%) severe adverse events included neutropenia (55.1%), thrombocytopenia (33.7%), anemia (30.6%), febrile neutropenia (12.2%), fatigue (11.2%), and anorexia (10.2%). In conclusion, POM and POM/DEX showed substantial efficacy against RRMM, but new combination therapies with POM are needed to improve efficacy further without causing hematologic toxicities.

引用

页码：541 / 550

页数：10

共 50 条

[11] Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma
Mark, Tomer M.
Boyer, Angelique
Rossi, Adriana C.
Kwon, Dennis
Pearse, Roger N.
Zafar, Faiza
Pekle, Karen
Tegnestam, Linda
Jayabalan, David
Ely, Scott A.
Coleman, Morton
Chen-Kiang, Selina
Niesvizky, Ruben
BLOOD, 2013, 122 (21)
[12] ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
Mark, Tomer M.
Boyer, Angelique
Rossi, Adriana C.
Shah, Manan
Pearse, Roger N.
Zafar, Faiza
Pekle, Karen
Tegnestam, Linda
Sacris, Erlinda A.
Greenberg, June
Speaker, Stephanie
Jayabalan, David
Ely, Scott A.
Coleman, Morton
Chen-Kiang, Selina
Niesvizky, Ruben
BLOOD, 2012, 120 (21)
[13] Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.
Rossi, Adriana C.
Mark, Tomer Martin
Rodriguez, Melissa
Shah, Manan
Quinn, Ryann
Pearse, Roger N.
Zafar, Faiza
Pekle, Karen
Speaker, Stephanie
Jayabalan, David
Ely, Scott
Coleman, Morton
Chen-Kiang, Selina
Niesvizky, Ruben
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[14] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Chen, Christine I.
Bahlis, Nizar
Gasparetto, Cristina
Tuchman, Sascha A.
Lipe, Brea C.
Baljevic, Muhamed
Kotb, Rami
Sutherland, Heather J.
Bensinger, William I.
Sebag, Michael
Leblanc, Richard
Venner, Christopher P.
Schiller, Gary J.
Lentzsch, Suzanne
Callander, Natalie Scott
Sheehan, Heidi
Chai, Yi
Kai, Kazuharu
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
White, Darrell J.
BLOOD, 2019, 134
[15] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Yee, Andrew J.
Laubach, Jacob P.
Campagnaro, Erica L.
Lipe, Brea C.
Nadeem, Omar
Friedman, Robb S.
Cole, Craig E.
O'Donnell, Elizabeth K.
Bianchi, Giada
Branagan, Andrew R.
Schlossman, Robert L.
Shapiro, Samantha J.
Harrington, Cynthia C.
Burke, Jill N.
Gammon, Marilyn T.
Lively, Kathleen J.
Reimonn, Cassandra A.
Andrade, Danielle X.
Redd, Robert
Lohr, Jens G.
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur S.
BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
[16] Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Garderet, Laurent
Kuhnowski, Frederique
Berge, Benoit
Roussel, Murielle
Escoffre-Barbe, Martine
Lafon, Ingrid
Facon, Thierry
Leleu, Xavier
Karlin, Lionel
Perrot, Aurore
Moreau, Philippe
Marit, Gerald
Stoppa, Anne-Marie
Royer, Bruno
Chaleteix, Carine
Tiab, Mourad
Araujo, Carla
Lenain, Pascal
Macro, Margaret
Voog, Eric
Benboubker, Lofti
Allangba, Olivier
Jourdan, Eric
Orsini-Piocelle, Frederique
Brechignac, Sabine
Eveillard, Jean-Richard
Belhadj, Karim
Wetterwald, Marc
Pegourie, Brigitte
Jaccard, Arnaud
Eisenmann, Jean-Claude
Glaisner, Sylvie
Mohty, Mohamad
Hulin, Cyrille
Avet-Loiseau, Herve
Mathiot, Claire
Attal, Michel
BLOOD, 2018, 132 (24) : 2555 - 2563
[17] OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Matsue, Kosei
Sunami, Kazutaka
Suzuki, Kenshi
Takezako, Naoki
Shinagawa, Atsushi
Sakurai, Sanae
Tamakoshi, Hiromi
Biyukov, Tsvetan
Peluso, Teresa
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E270 - E271
[18] Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma
Hoy, Sheridan M.
DRUGS, 2017, 77 (17) : 1897 - 1908
[19] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
Matsue, Kosei
Iwasaki, Hiromi
Chou, Takaaki
Tobinai, Kensei
Sunami, Kazutaka
Ogawa, Yoshiaki
Kurihara, Mari
Midorikawa, Shuichi
Zaki, Mohamed
Doerr, Thomas
Iida, Shinsuke
CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
[20] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
Guidetti, Anna
Prada, Claudia Paba
Laubach, Jacob P.
Varga, Cindy
Maglio, Michelle E.
McKenney, Mary
Doss, Deborah
Schlossman, Robert L.
Mitsiades, Constantine
Hideshima, Teru
Gorgun, Gullu T.
Ghobrial, Irene M.
Raje, Noopur
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108

← 1 2 3 4 5 →